期刊文献+

逆转录病毒介导Ⅰ型单纯疱疹病毒胸腺嘧啶核苷激酶基因转导卵巢癌细胞的研究 被引量:9

TransferofThymidineKinaseGeneofHerpesSimplexVirusMediatedbyRetrovirusVectorintoOvarianCancerCels
原文传递
导出
摘要 目的:探讨将Ⅰ型单纯疱疹病毒胸腺嘧啶核苷激酶基因(HSV-tk)/丙氧鸟苷基因治疗系统应用于卵巢癌的治疗。方法:应用产病毒包装细胞(VPC)/HSV-tka和VPC/HSV-tkc的培养液分别感染卵巢上皮癌细胞系AO和3AO,以G-418筛选转导阳性克隆,并以丙氧乌苷杀伤阳性克隆。结果:VPC/HSV-tkc培养液对AO细胞的感染滴度为9.3×100000;以1∶1000稀释度的VPC/HSV-tkc培养液与以1∶10稀释度的VPC/HSV-tka培养液作转导所获得的阳性克隆数相近;且所有阳性克隆在含有10μg/ml丙氧鸟苷的培养液中均发生完全死亡。 Objective:Tosearchfortheapplicationoftheretrovirusvector(RV)/herpessimplexvirustypeⅠthymidinekinasegene(HSV-tk)/ganciclovior(GCV)genetherapeuticsysteminthetreatmentofovariancancer.Methods:Twokindsofvector-producingcels(VPC)whichcanpro-duceretrovirusvectorsconstructedtocontainneoRgeneandtwokindsofHSV-tkgenes(markedas“HSV-tka”and“HSV-tkc”)wereemployedtotransferthosegenesintoovariancancerAO,3AOcellines.Andtheresponseofthoseanti-G418clonestoGCVtherapywasobserved.Results:InthetransductiontoAOcels,thevectortiteroftheVPC/HSV-tkcculturewas9.3×100000cfu/ml,andtherewere263anti-G418clonesinthe25cm2celcultureflaskinwhich1∶1000dilutedVPC/HSV-tkcculturewasadded,and235clonesinasimilarflaskinwhich1∶10dilutedVPC/HSV-tkaculturewasadded.Furthermore,aloftheHSV-tkcpositiveclonesexposedto10μg/mlGCVcouldbeeliminated,and96%ofthoseclonesdiedin5daysafterGCVwasused.Conclusions:Theappli-cationoftheRV/HSV-tk/GCVsystemisverypromisinginthegenetherapyofovariancancer.
出处 《中华妇产科杂志》 CSCD 北大核心 1996年第11期664-666,共3页 Chinese Journal of Obstetrics and Gynecology
基金 国家自然科学基金
关键词 卵巢肿瘤 逆转录病毒科 胸苷激酶 OvariancancerRetroviridaeHerpesvirusⅠ humanThymidinekinase
  • 相关文献

参考文献1

  • 1卢圣栋,现代分子生物学实验技术,1993年

同被引文献65

  • 1Kanai F, Kawakani T, Hamade, et al. Adenoviras-mediated transduction of E. coil uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil [ J ]. CancerRes, 1998, 58(9) : 1946-1951.
  • 2Uckert W, Kammertons T, Haack K, et al. Double suicide gene(cytosine deaminase and herpes simplex virus thymidine kinase )but not single gene transfer allows reliable elimination of tumor cells in vivo [J]. Hum Gene Ther, 1998, 9(6) : 855-865.
  • 3Furman PA, Mcguirt PV, Keller PM, et al. Inhibition of ACV of cell growth and DNA synthesis of cells biochcmically transformed with herpes virus genetic information[J]. Virol, 1980, 102: 420-430.
  • 4Freeman SM, Abbound CN, Whartenby KA, et al. The "bystander effectn : Tumor regression when a fraction of the tumor mass is genetically modified[J]. Cancer Res, 1993, 53 : 5274-5283.
  • 5Moolten FL. Tumor Chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy[J]. Cancer Res, 1986, 46: 5276-5281.
  • 6Moolten FL, Wells J-M, Heyman RA, et al. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene[J]. Hum C, ene Ther, 1990, 1 : 125-134.
  • 7Moolten FL, Wells JIM. Curability of tumors bearing herpes thymidine kitmse genes transferred by retroviml vectors[J]. J Nail Cancer Inst, 1990, 82(4) : 297-300.
  • 8Behbakht K, Benjamin I, et al. Adenovirus-mediated gene therapy of ovarian cancer in a mouse model [ J ]. Am J Obstet Gynecol,1996, 175(5): 1260-1265.
  • 9Tong XW, Block A, Chen SH, et al. in vivo gene therapy of ovarian cancer by adenoviras-mediated thymidine kinase transduction and gancidovir administration [ J ]. Gynecol Oncol, 1996, 61 :175-179.
  • 10Al-hendy A, Auersperg N. Applying the herpes simplex virus thymidine ki~gancicdovir approach to ovarian cancer: An effective in vitro drug-sensitization system [ J ]. Gynecol Obstet Invest,1997, 43(4) : 268-275.

引证文献9

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部